综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

USEUROPEAFRICAASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Health is wealth, going private 'is the future'

By Chen Yingqun in Beiing, Cecily Liu in London and Ren Qi in Beijing | China Daily | Updated: 2013-07-15 07:25

His council "has realized the importance of working with China. The investment and organization of the stem cell biology field in China has seen a sea change over the last few years", Buckle says.

The two partners have currently funded nine groups of researchers. "Each group involves a UK lab and a Chinese lab because we want to encourage scientists from both countries to work together," says Buckle.

Despite China's rising standards of medical research, it still needs to improve the environment for large clinical trials, says Rury Holman, a professor of diabetic medicine and director of the University of Oxford Diabetes Trials Unit.

"China needs more trained people in hospitals to do clinical research. It also needs to develop a research culture that provides doctors and research nurses with the dedicated space and time needed to undertake research in hospitals," Holman says.

Holman is currently leading a team of academics in researching how to reduce the risk of cardiovascular disease and diabetes in China. Starting in 2008, this large trial is expected to finish in 2017. It is collecting data over six years from 7,500 patients across 150 Chinese hospitals.

This project and other research programs also seek to discover the long-term effects of specific diabetes drugs for the Chinese population because China often lacks such data and its government guidelines on diabetes drugs rely heavily on guidelines of Western countries.

"China's State Food and Drug Administration will have the option of using the results of our research work to create its own guidelines on diabetes, which will include, for example, drugs for first-line treatment and then how to personalize drugs for patients," he says.

Looking to the future, China's healthcare sector will provide many more opportunities for foreign players, especially in the fields of drugs, medical insurance investment, IT and medical equipment, says Norbert Meyring, head of KPMG Life Science in China and Asia-Pacific. "I assume there will be an 18 percent to 20 percent annual growth in Chinese drug spending through 2015 due to robust economic growth and a rising middle class."

He says China's medical sector and basic medical insurance system are opening up to private and foreign capital and, at the same time, more global IT providers are entering China's medical market to drive a faster transformation in the country's healthcare system.

"China's healthcare reform will also trigger a vast demand in the medical devices segment. China's medical device market is expected to become the world's second-largest by 2015," Meyring says.

Previous 1 2 3 4 Next

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
开鲁县| 无锡市| 天等县| 石渠县| 诸暨市| 磐安县| 仪陇县| 剑河县| 永定县| 彰武县| 玛沁县| 镇坪县| 东兴市| 荣成市| 星子县| 金阳县| 顺义区| 平潭县| 兴山县| 兴隆县| 齐河县| 庆阳市| 庆城县| 八宿县| 周宁县| 家居| 海淀区| 贵德县| 宣威市| 日土县| 吉水县| 红桥区| 思南县| 大同市| 石渠县| 新巴尔虎右旗| 徐州市| 安仁县| 沈丘县| 长丰县| 阳朔县|